B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 32,194 Exact Sciences Co. (NASDAQ:EXAS)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm bought 32,194 shares of the medical research company's stock, valued at approximately $2,193,000.

A number of other institutional investors also recently bought and sold shares of EXAS. William Blair Investment Management LLC acquired a new stake in Exact Sciences in the 2nd quarter worth approximately $163,896,000. Sculptor Capital LP purchased a new position in Exact Sciences during the 2nd quarter worth approximately $32,819,000. Samlyn Capital LLC purchased a new position in Exact Sciences during the 2nd quarter worth approximately $30,426,000. Iron Triangle Partners LP purchased a new position in Exact Sciences during the 1st quarter worth approximately $48,342,000. Finally, Armistice Capital LLC raised its position in Exact Sciences by 91.6% during the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company's stock worth $59,154,000 after buying an additional 669,438 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Brian Baranick sold 929 shares of the business's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now owns 13,687 shares of the company's stock, valued at approximately $958,090. The trade was a 6.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin T. Conroy purchased 19,500 shares of the stock in a transaction dated Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.36% of the company's stock.

Exact Sciences Price Performance

EXAS traded down $0.16 on Friday, hitting $52.91. 2,004,102 shares of the company's stock were exchanged, compared to its average volume of 2,642,613. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The firm has a 50-day moving average price of $64.79 and a 200-day moving average price of $55.90. The stock has a market cap of $9.79 billion, a price-to-earnings ratio of -45.22 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm's revenue was up 12.8% on a year-over-year basis. As a group, equities analysts anticipate that Exact Sciences Co. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on EXAS shares. Evercore ISI reduced their price target on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Stifel Nicolaus reduced their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group cut their target price on shares of Exact Sciences from $75.00 to $65.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. TD Cowen cut their target price on shares of Exact Sciences from $90.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, Benchmark cut their target price on shares of Exact Sciences from $67.00 to $65.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $74.47.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.